Exogen Biotechnology provides services for measuring DNA double-strand breaks (DSB) in cells and assessing the capacity of cells to repair DNA DSB. Exogen’s technological platform for assessing DNA damage and repair capacities was originally developed at the Lawrence Berkeley National Laboratory by a team of scientists and engineers.
Our services include:
Standard sample shipment requirements:
For analysis of live cells, samples should be shipped in media with serum and kept at 40 degrees with a cold pack and a transit time of less than 12 hours. For DNA damage foci quantitative analysis of fixed specimen, we accept slides or 96 well optical-bottom plates shipped with a cold pack. For small blood samples acquired using our finger-prick collection kit, samples should be sent back at room temperature.
Please request a quote for more details.
Sylvain Costes, Ph.D. - Co-Founder and CEO
Dr. Costes received his Ph.D. in Nuclear engineering from UC Berkeley. He is considered a world-renowned expert in high-throughput fluorescence microscopy and imaging and in radiation risk modeling. He has more than thirty peer-reviewed publications, and his work has been cited more than one-thousand times over the past eight years. After his postdoctoral fellowship in the Mathematics Department at UC Berkeley, he joined the National Cancer Institute where he developed novel quantitative tools for fluorescence 4D microscopy. Dr. Costes joined the Lawrence Berkeley National Laboratory in 2004, where he developed the novel technology being used by Exogen to assess DNA repair in living human cells.
Jonathan Tang, Ph.D. - Co-Founder
Dr. Tang received his Ph.D. in Bioengineering from UC Berkeley and UC San Francisco and his B.S. in Biomedical Engineering at Columbia University. He is interested in the development and integration of engineering and computational tools with wet-lab experiments to study carcinogenesis with the overall goal of prevention and treatment of cancer. He joined the Costes group at the Lawrence Berkeley National Laboratory in 2009 as a postdoctoral research fellow to develop computational and bioinformatics tools for projects funded by NASA, the National Cancer Institute, and the Department of Energy to study the progression of breast cancer and the carcinogenic effects of ionizing radiation on biological tissue.
Steven Yannone, Ph.D. - Principal Investigator
Dr. Yannone earned his Ph.D. in Biochemistry & Molecular Biology from UC Irvine and performed his postdoctoral work at Los Alamos National Laboratory. Dr. Yannone has led his research group at the Lawrence Berkeley National Laboratory since 1999 and authored over thirty scientific articles that are cited over one-thousand times in the scientific literature. He is the recipient of numerous awards for both his research and his mentorship of students and junior scientists. He is widely recognized for his expertise in protein biochemistry and specifically for his work on enzymes impacting human immunity and DNA repair. Dr. Yannone co-developed Exogen’s blood-based assays and is a named inventor on the intellectual property licensed to Exogen.
DNA Repair Efficiency Assay:
High-throughput, computer-automated measurement of DNA damage (double-strand break) levels in live cells at various time points following insult by a DNA damaging agent (ionizing radiation). DNA double-strand breaks are quantified by computer-automated counting of foci (gamma-H2AX or 53BP1)
DNA Damage Assay:
High-throughput, computer-automated measurement of DNA double-strand break levels in live or fixed cells by counting foci (gamma-H2AX or 53BP1).
Exogen Biotechnology, Inc. has not received any reviews.
Exogen Biotechnology, Inc. has not received any endorsements.